The diagnosis of glaucoma, an ocular pathology, fits in the realm of expertise of general ophthalmologist committed to reduce the burden of serious vision-robbing diseases or sight-threatening diseases. A key drive for the strides in the glaucoma diagnostics market comes from the use of simple instrumentation in diagnosing the symptoms of glaucoma. Advancements in imaging devices have helped ophthalmologists in charting out a comprehensive plan for managing glaucoma.
The disease the optic nerve is one of the chronically progressive disorders that lead to blindness. Thus, the eye care industry has seen several new avenues on the back of the fact that untreated glaucoma is the one of the leading causes of irreversible blindness in the patient population, according to a study by numerous vision loss expert groups analyzing the epidemiology of glaucoma. Some of the methods used in diagnosis are the use of slit lamps, gonioscopy, dilated stereoscopic evaluation, and applanation tonometry. A comprehensive eye examination is often recommended for the family for some types of glaucoma such as primary open angle glaucoma (POAG).
The study presents a detailed assessment of clinical developments and epidemiology trends shaping the lucrative avenues in the glaucoma diagnostics market. The research analysts strive to evaluate the impact of these trends on the technological developments and product innovations. The study also highlights the role of public policies and the changing status of healthcare in various emerging markets.
The high prevalence of glaucoma in young and older adults is a key driver for the prospects in the glaucoma diagnostics market. The prevalence as well as the burden is particularly for high open-angle glaucoma, especially in the cohort 40 – 80 years. Rise in prevalence with age has also spurred the need for diagnostic evaluation of glaucoma in early stages, thus boosting the growth of the glaucoma diagnostics market.
The presence of numerous risk factors are advanced age, high myopia, family history, and elevated intraocular pressure. Elevated intraocular pressure among these have attracted the attention since it is a crucial risk factor for open-angle glaucoma lowering which can substantially reduce the risk of the glaucoma.
Various countries have started regular screening examinations for glaucoma. However, medical technology companies and device makers are concerned about low sensitivity and specificity of the various common tests. Also, there is a need for randomized and controlled trials pertaining to high risk groups present a huge opportunity in the glaucoma diagnostics market. Lack of coverage by statutory health insurance providers also present developments in the regulatory landscape.
Some of the key players in the glaucoma diagnostics market are Carl Zeiss Meditec, Haag-Streit Holding, Leica Microsystems, Topcon Corporation, and Heidelberg Engineering.
On the regional front, North America and Europe have been remarkably lucrative markets for the past few years. The presence of revenue streams has been fueled by the presence of large target population and advances in evaluation techniques, such as in morphometric techniques. Rise in prevalence of glaucoma and the growing awareness of this condition in Asia Pacific nations has also led medical device companies shift toward the regional market. Advancing eye care infrastructure will further spur the demand for glaucoma diagnostics in some of the emerging economies in the region.